Regeneron记录了为提高效率和关注核心疗法而进行重组的83M美元费用。 Regeneron records $83M charge for restructuring to boost efficiency and focus on core therapies.

Regenenron制药公司将记录8 300万美元的收费,原因是其业务重组,目的是提高长期效率和侧重于核心治疗领域。 Regeneron Pharmaceuticals is set to record an $83 million charge due to a restructuring of its operations, aimed at improving long-term efficiency and focusing on core therapeutic areas. 该公司没有披露关于裁员或设施关闭的具体细节,但表示此举支持可持续增长。 The company did not disclose specifics on job cuts or facility closures but said the move supports sustainable growth. 一次性支出将影响其本季度成果,尽管Regeneneron仍然有信心在目前行业对成本管理和赢利情况进行审查的情况下,在编审中和今后业绩方面保持信心。 The one-time expense will impact its current quarter results, though Regeneron remains confident in its pipeline and future performance amid ongoing industry scrutiny over cost management and profitability.